Physician profile
Ryan L Geraets
NPI 1154441608
$7,382.92
in general payments reported to CMS, 2019-2025
17 companies · $106 in 2025
The $106 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,048 · 2020: $722 · 2021: $1,696 · 2022: $3,168 · 2023: $556 · 2024: $87.14 · 2025: $106.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $706 · Education: $43.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $705.85 |
| Education | $43.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| US Retina LLC | $5,202.05 | 2019-2022 | |
| Alimera Sciences, INC. | $1,749.14 | 2021-2024 | Yutiq, Iluvien |
| Dutch Ophthalmic, USA | $83.96 | 2019 | |
| Abbvie INC. | $48.04 | 2022-2025 | |
| Astrazeneca Pharmaceuticals LP | $43.25 | 2025 | Enhertu |
| Biogen, INC. | $35.00 | 2022-2025 | Byooviz |
| Allergan, INC. | $27.81 | 2021 | |
| Alcon Vision LLC | $27.01 | 2023 | Clareon |
| Genentech USA, INC. | $26.32 | 2021-2023 | Lucentis, Vabysmo |
| Ani Pharmaceuticals, INC. | $25.79 | 2025 | Iluvien |
| Apellis Pharmaceuticals, INC. | $20.07 | 2023 | Syfovre |
| Astellas Pharma US INC | $19.56 | 2023 | |
| Eyepoint US, INC. | $17.97 | 2023 | |
| Spark Therapeutics, INC. | $16.50 | 2019 | |
| Bausch & Lomb Americas INC. | $14.53 | 2023 | Xipere |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $13.21 | 2021 | |
| Dexcom, INC. | $12.71 | 2023 | Dexcom G6 Transmitter |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$197,862.00 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ryan Geraets listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.